Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.,The New England Journal of Medicine

当前位置： X-MOL 学术 › N. Engl. J. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2017-08-27 , DOI: 10.1056/nejmoa1707914
Paul M Ridker ₁ , Brendan M Everett ₁ , Tom Thuren ₁ , Jean G MacFadyen ₁ , William H Chang ₁ , Christie Ballantyne ₁ , Francisco Fonseca ₁ , Jose Nicolau ₁ , Wolfgang Koenig ₁ , Stefan D Anker ₁ , John J P Kastelein ₁ , Jan H Cornel ₁ , Prem Pais ₁ , Daniel Pella ₁ , Jacques Genest ₁ , Renata Cifkova ₁ , Alberto Lorenzatti ₁ , Tamas Forster ₁ , Zhanna Kobalava ₁ , Luminita Vida-Simiti ₁ , Marcus Flather ₁ , Hiroaki Shimokawa ₁ , Hisao Ogawa ₁ , Mikael Dellborg ₁ , Paulo R F Rossi ₁ , Roland P T Troquay ₁ , Peter Libby ₁ , Robert J Glynn ₁ ,

Affiliation

From the Center for Cardiovascular Disease Prevention (P.M.R., B.M.E., J.G.M., R.J.G.) and the Cardiovascular Division (P.M.R., B.M.E., P.L.), Brigham and Women's Hospital, Harvard Medical School, Boston; Novartis, East Hanover, NJ, and Basel, Switzerland (T.T., W.H.C.); Baylor College of Medicine, Houston (C.B.); Federal University of São Paulo (F.F.) and the Heart Institute (InCor), University of São Paulo Medical School (J.N.), São Paulo, and Faculdade Evangelica de Medicina do Parana, Curitiba (P.R.F.R.) - all in Brazil; Deutsches Herzzentrum München, Technische Universität München, German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich (W.K.), and the Department of Cardiology and Berlin-Brandenburg Center for Regenerative Therapies, Charité Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin (S.D.A.) - both in Germany; Academic Medical Center of the University of Amsterdam, Amsterdam (J.J.P.K.), Alkmaar Medical Center, Alkmaar (J.H.C.), and VieCuri Medical Center for Northern Limburg, Venlo (R.P.T.T.) - all in the Netherlands; Manipal Hospital, St. John's Research Institute, Bangalore, India (P.P.); Pavol Jozef Safarik University, Kosice, Slovakia (D.P.); McGill University, Montreal (J.G.); First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic (R.C.); Cordoba Hospital, Cordoba, Argentina (A.L.); University of Szeged, Szeged, Hungary (T.F.); City Hospital No. 64, Medical Institute RUDN University, Moscow (Z.K.); Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania (L.V.-S.); University of East Anglia, Norwich Medical School, Norwich, United Kingdom (M.F.); Tohoku University Hospital, Sendai (H.S.), and National Cerebral and Cardiovascular Center, Osaka (H.O.) - both in Japan; and Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden (M.D.).

Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.)

中文翻译：

Canakinumab抗动脉粥样硬化性疾病的抗炎治疗。

每3个月以150 mg的剂量使用canakinumab靶向白细胞介素-1β先天性免疫途径的抗炎治疗导致的复发性心血管事件发生率显着低于安慰剂，而与血脂水平降低无关。（由诺华资助； CANTOS ClinicalTrials.gov编号，NCT01327846。）

更新日期：2017-09-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>